The Osaka High Court on Thursday upheld a lower court ruling that sentenced a former doctor to two years and six months in ...
Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...
Clene (NASDAQ: CLNN) announced new long-term survival data from the HEALEY ALS Platform Trial, showing that treatment with CNM-Au8® 30 mg significant ...
Clene, Inc. (Nasdaq: CLNN) and its subsidiary, Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment ...
Under current regulations, spouses can receive benefits only if the veteran lived with the disability for at least eight years before dying.
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the presentation of eleven abstracts covering research in amyotrophic lateral sclerosis (ALS) at the 2025 Muscular Dystrophy Association ...
IEEE Spectrum on MSN19h
New Brain Tech Gives Voice to ALS PatientsA myotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects muscle control, and most ...
Clene (CLNN) and its subsidiary, Clene Nanomedicine announced new evidence from a cross-regimen, post hoc analysis of long-term survival in ...
AKGsOVIHAMS, a leading healthcare institution, has marked progress in treating ALS using integrative medicine. Known for combining conventional and alternative therapies, the institute has shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback